New Study Published in Nature Provides Further Evidence that COVID-19 Vaccine Induced T-Cell Response Targets Known SARS-CoV-2 Variants of Concern
The study provides further evidence that the T-cell response may contribute to protection from COVID-19.
- The study provides further evidence that the T-cell response may contribute to protection from COVID-19.
- In the multinational phase 3 ENSEMBLE trial, participants given Johnson & Johnsons vaccine experienced similar efficacy against the B.1.351 variant.
- Mapping exactly how the variants impact different parts of the virus can indicate if the immune response is likely to be affected.
- The tool can be used to study the T-cell immune response for vaccine research across COVID-19 variants., mapping across >160KSARS-CoV-2-specific antigen-TCR sequence-level data.